DDInter1233 DDInter899
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Mitotane {u} (Compound) binds {v} (Gene) CYP11B1
Mitotane {u} (Compound) upregulates {v} (Gene) ADGRE5
Mitotane {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Mitotane {u} (Compound) downregulates {v} (Gene) PEG10
Mitotane {u} (Compound) causes {v} (Side Effect) Digestion impaired
Mitotane (Compound) resembles Carbinoxamine (Compound)
Mitotane (Compound) binds CYP11B1 (Gene)
Mitotane (Compound) upregulates ADGRE5 (Gene)
Mitotane (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class)
Mitotane (Compound) downregulates PEG10 (Gene)
Mitotane (Compound) causes Digestion impaired (Side Effect)